Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice
- 16 November 2011
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 55 (2) , 509-519
Abstract
Aims/hypothesis The TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways have been shown to play a critical role in the development of renal fibrosis and inflammation in diabetic nephropathy. We therefore examined whether targeting these pathways by a kidney-targeting Smad7 gene transfer has therapeutic effects on renal lesions in the db/db mouse model of type 2 diabetes. Methods We delivered Smad7 plasmids into the kidney of db/db mice using kidney-targeting, ultrasound-mediated, microbubble-inducible gene transfer. The histopathology, ultrastructural pathology and pathways of TGF-β/SMAD2/3-mediated fibrosis and NF-κB-dependent inflammation were evaluated. Results In this mouse model of type 2 diabetes, Smad7 gene therapy significantly inhibited diabetic kidney injury, compared with mice treated with empty vectors. Symptoms inhibited included: (1) proteinuria and renal function impairment; (2) renal fibrosis such as glomerular sclerosis, tubulo-interstitial collagen matrix abundance and renal inflammation, including Inos (also known as Nos2), Il1b and Mcp1 (also known as Ccl2) upregulation, as well as macrophage infiltration; and (3) podocyte and endothelial cell injury as demonstrated by immunohistochemistry and/or electron microscopy. Further study demonstrated that the improvement of type 2 diabetic kidney injury by overexpression of Smad7 was associated with significantly inhibited local activation of the TGF-β/SMAD and NF-κB signalling pathways in the kidney. Conclusions/interpretation Our results clearly demonstrate that kidney-targeting Smad7 gene transfer may be an effective therapy for type 2 diabetic nephropathy, acting via simultaneous modulation of the TGF-β/SMAD and NF-κB signalling pathways.Keywords
This publication has 50 references indexed in Scilit:
- The Protective Role of Smad7 in Diabetic Kidney Disease: Mechanism and Therapeutic PotentialDiabetes, 2011
- Expression patterns of connective tissue growth factor and of TGF-β isoforms during glomerular injury recapitulate glomerulogenesisAmerican Journal of Physiology-Renal Physiology, 2010
- The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic NephropathyDiabetes, 2010
- Peripheral osmotic stimulation inhibits the brain's innate immune response to microdialysis of acidic perfusion fluid adjacent to supraoptic nucleusAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- APPLICATION OF AN ADENOVIRAL VECTOR ENCODING SOLUBLE TRANSFORMING GROWTH FACTOR‐β TYPE II RECEPTOR TO THE TREATMENT OF DIABETIC NEPHROPATHY IN MICEClinical and Experimental Pharmacology and Physiology, 2008
- A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic NephropathyJournal of the American Society of Nephrology, 2008
- Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin TreatmentHypertension, 2008
- Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuriaAmerican Journal of Physiology-Renal Physiology, 2007
- Endothelial Nitric Oxide Synthase Deficiency Produces Accelerated Nephropathy in Diabetic MiceJournal of the American Society of Nephrology, 2006
- Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidneyKidney International, 2005